Literature DB >> 12909073

Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile.

Ole Lund1, Kristian Emmertsen, Inge Dørup, Finn T Jensen, Christian Flø.   

Abstract

BACKGROUND: Previous studies have suggested that regression of hypertrophy may be the underlying determinant of longevity and left ventricular function after valve replacement (AVR) for aortic stenosis (AS). The potential for hypertrophy regression could therefore be related to the preoperative risk profile.
METHODS: Ninety-one consecutive patients with AS had a "project" Doppler-echo and radionuclide ventriculography in addition to the standard investigation programme prior to AVR with a disc valve (19-29mm, n=82), a caged ball valve (26-29mm, n=8), or a stented porcine valve (26mm, n=1); 49 (group A) were selected for a serial follow-up study while 42 served as controls (group B). Forty-two group A patients took part in a 1.5-year examination while 47 (26 group A, 21 group B) patients were studied at 10 years.
RESULTS: Groups A and B were comparable as regards all pre- and intra-operative data including left ventricular mass index (LVMi). A previously developed preoperative prognostic index (PI) separated the patients into groups with low (n=23), intermediary (n=19) and high risk (n=49) with 10-year survivals of 87%, 58% and 43% (P<0.01). LVMi dropped from 202+/-58g/m(2)preoperatively to 152+/-45g/m(2)(P<0.0001) at 1.5 years, and 139+/-40g/m(2)(P<0.0001) at 10 years (three and six patients, respectively, with paravalvular leak or mitral regurgitation excluded). PI correlated with preoperative (r=0.51, P<0.001), 1.5-year (r=0.46, P<0.01), and 10-year LVMi (r=0.41, P<0.01). Also preoperative left ventricular ejection fraction correlated with the three LVMi measurements. Patients with systemic hypertension had higher LVMi at 1.5 years (193+/-42, n=6 vs 144+/-42, n=33, P<0.05) and 10 years (175+/-39, n=12 vs 124+/-31g/m(2), n=29, P<0.001). Patients with low, intermediary or high PI, excluding those with hypertension, had 1.5-year LVMi of 110+/-35 (n=8), 134+/-43 (n=9) and 164+/-33g/m(2)(n=16; P<0.01), respectively, and 10-year LVMi of 116+/-25 (n=17), 126+/-27 (n=6), and 146+/-41g/m(2)(n=6; P<0.05), respectively. There was no relation between LVMi at 1.5 or 10 years and peak or mean Doppler gradient, prosthetic valve size, or valve size index.
CONCLUSIONS: Left ventricular hypertrophy regression for patients who survived up to 10 years after AVR for AS is dependent on the preoperative risk profile indicating that irreversible myocardial disease is the underlying factor. Systemic hypertension is an important factor in its own right.

Entities:  

Mesh:

Year:  2003        PMID: 12909073     DOI: 10.1016/s0195-668x(03)00316-6

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  23 in total

1.  Regression of left ventricular mass after implantation of the sutureless 3f Enable aortic bioprosthesis.

Authors:  Giovanni Concistrè; Antonio Miceli; Federica Marchi; Francesca Chiaramonti; Mattia Glauber; Marco Solinas
Journal:  Tex Heart Inst J       Date:  2015-04-01

2.  Left ventricular mass regression after sutureless implantation of the Perceval S aortic valve bioprosthesis: preliminary results.

Authors:  Giuseppe Santarpino; Steffen Pfeiffer; Francesco Pollari; Giovanni Concistrè; Ferdinand Vogt; Theodor Fischlein
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-10-08

3.  Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.

Authors:  Brian R Lindman; Alan Zajarias; José A Madrazo; Jay Shah; Brian F Gage; Eric Novak; Stephanie N Johnson; Murali M Chakinala; Tara A Hohn; Mohammed Saghir; Douglas L Mann
Journal:  Circulation       Date:  2012-03-25       Impact factor: 29.690

Review 4.  Assessment of left ventricular function in aortic stenosis.

Authors:  Alper Ozkan; Samir Kapadia; Murat Tuzcu; Thomas H Marwick
Journal:  Nat Rev Cardiol       Date:  2011-06-14       Impact factor: 32.419

5.  Patterns of left ventricular remodeling in aortic stenosis: therapeutic implications.

Authors:  Sammy Elmariah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-07

6.  N-terminal pro-B-type natriuretic peptide measurement is useful in predicting left ventricular hypertrophy regression after aortic valve replacement in patients with severe aortic stenosis.

Authors:  Mirae Lee; Jin-Oh Choi; Sung-Ji Park; Eun Young Kim; PyoWon Park; Jae K Oh; Eun-Seok Jeon
Journal:  Heart Asia       Date:  2015-04-27

Review 7.  Challenges and opportunities in improving left ventricular remodelling and clinical outcome following surgical and trans-catheter aortic valve replacement.

Authors:  Xu Yu Jin; Mario Petrou; Jiang Ting Hu; Ed D Nicol; John R Pepper
Journal:  Front Med       Date:  2021-05-28       Impact factor: 4.592

8.  A case of critical aortic stenosis masquerading as acute coronary syndrome.

Authors:  Siddharth A Wayangankar; Tarun W Dasari; Pedro M Lozano; Karen J Beckman
Journal:  Cardiol Res Pract       Date:  2010-07-20       Impact factor: 1.866

9.  Risk stratification and management of aortic stenosis with concomitant left ventricular dysfunction.

Authors:  Matthew L Steinhauser; Peter H Stone
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-12

10.  Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations.

Authors:  Brian R Lindman; William J Stewart; Philippe Pibarot; Rebecca T Hahn; Catherine M Otto; Ke Xu; Richard B Devereux; Neil J Weissman; Maurice Enriquez-Sarano; Wilson Y Szeto; Raj Makkar; D Craig Miller; Stamatios Lerakis; Samir Kapadia; Bruce Bowers; Kevin L Greason; Thomas C McAndrew; Yang Lei; Martin B Leon; Pamela S Douglas
Journal:  JACC Cardiovasc Interv       Date:  2014-06       Impact factor: 11.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.